Glargine ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
299	嚢胞性線維症	3

299. 嚢胞性線維症

---

臨床試験数 : 1,696 /  薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00483769 (ClinicalTrials.gov)	February 2006	6/6/2007	One Year Glargine Treatment in CFRD Children and Adolescents	One-Year Glargine-Treatment Can Ameliorate Clinical Features in Cystic Fibrosis Children and Adolescents With Glucose Derangements	Cystic Fibrosis;Glucose Metabolism Disorders	Drug: Glargine	Federico II University	NULL	Completed	3 Years	20 Years	Both	20	Phase 4	Italy
2	EUCTR2005-002135-27-IT (EUCTR)	06/07/2005	28/06/2005	Glargine insulin efficacy in Cystic Fibrosis patients with glucose intolerance and clinical deterioration	Glargine insulin efficacy in Cystic Fibrosis patients with glucose intolerance and clinical deterioration	Cystic Fibrosis patients with glucose intolerance MedDRA version: 6.1;Level: PT;Classification code 10011762	Trade Name: LANTUS*SC 5CAR3ML100UI/ML Product Name: NA Product Code: NA INN or Proposed INN: Insulin glargine	ISTITUTO GIANNINA GASLINI	NULL	Not Recruiting			Female: yes Male: yes			Italy
3	NCT00222521 (ClinicalTrials.gov)	April 2003	14/9/2005	Insulin Glargine Vs Standard Insulin Therapy	Comparison of Insulin Glargine Vs Standard Insulin Therapy in CFRD Without Fasting Hyperglycemia	Cystic Fibrosis Related Diabetes	Drug: Glargine insulin	University of Minnesota - Clinical and Translational Science Institute	Sanofi;Moran, Antoinette, M.D.	Completed	12 Years	N/A	Both	20	Phase 3	United States